Market Place
Sourcing Support
Nektar Therapeutics Closes $373.8M Public Offering
24 Apr 2026 //
PR NEWSWIRE
Nektar’s long-term Mid-Stage Alopecia Data fuel Phase 3 plans
20 Apr 2026 //
ENDPOINTS
Nektar Therapeutics Announces Proposed Public Offering
20 Apr 2026 //
FIRSTWORD PHARMA
Rezpegaldesleukin Phase 2B Data Revealed At 2026 AAD Meeting
28 Mar 2026 //
PR NEWSWIRE
Rezpegaldesleukin Ph2b Data Accepted For AAD 2026 Talks
20 Mar 2026 //
PR NEWSWIRE
Rezpegaldesleukin Ph2b Data To Be Presented At AAD 2026
20 Mar 2026 //
PR NEWSWIRE
Nektar Closes $460M Offering; Option Fully Exercised
13 Feb 2026 //
PR NEWSWIRE
Nektar’s Rezpeg Shows Mid-Stage Benefit in Atopic Dermatitis
11 Feb 2026 //
BIOSPACE
Nektar Therapeutics Announces Proposed Public Offering
10 Feb 2026 //
PR NEWSWIRE
Nektar Eczema Asset `Checked All Of The Boxes` In Phase 2
10 Feb 2026 //
FIERCE BIOTECH
Nektar Plans Conference Call On REZOLVE-AD Study Results
10 Feb 2026 //
PR NEWSWIRE BIO
Nektar To Discuss REZOLVE-AA Phase 2B Study Results In Alopecia
16 Dec 2025 //
PR NEWSWIRE
Rezpegaldesleukin Data From REZOLVE-AD Study Revealed at ACAAI
08 Nov 2025 //
PR NEWSWIRE
REZOLVE-AD Phase 2B Data On Rezpegaldesleukin Accepted For ACAAI
22 Oct 2025 //
PR NEWSWIRE
Nektar Provides More Dermatitis Drug Data
19 Sep 2025 //
BIOSPACE
Nektar Unveils REZOLVE-AD Ph 2b Data for Rezpegaldesleukin
18 Sep 2025 //
PR NEWSWIRE
Nektar`s REZOLVE-AD Ph 2b Results for Late-Breaker at EADV 2025
09 Sep 2025 //
PR NEWSWIRE
Nektar Therapeutics Prices $100 Million Public Offering
01 Jul 2025 //
PR NEWSWIRE
REZOLVE-AD Phase 2b Study: Rezpegaldesleukin Meets Endpoints
24 Jun 2025 //
PR NEWSWIRE
Nektar to Announce Top-line Data from REZOLVE-AD Study on June 24
23 Jun 2025 //
PR NEWSWIRE
Nektar Therapeutics Reports First Quarter 2025 Financial Results
08 May 2025 //
PR NEWSWIRE
Nektar to Evaluate Rezpegaldesleukin in New Type 1 Diabetes
24 Feb 2025 //
PR NEWSWIRE
Nektar`s Fast Track Designation for Rezpegaldesleukin in Dermatitis
10 Feb 2025 //
PR NEWSWIRE
Nektar Presents Late-Breaking Phase 2 Results of NKTR-255 at SITC
07 Nov 2024 //
PR NEWSWIRE
Nektar Reaches Agreement to Sell PEGylation Manufacturing Business
04 Nov 2024 //
PR NEWSWIRE
Nektar Publishes Ph 1B For Rezpegaldesleukin In Skin Diseases
29 Oct 2024 //
PR NEWSWIRE
Nektar and Collaborators Present Data on NKTR-255 in Presentation
11 Dec 2023 //
PR NEWSWIRE
Nektar Presents New Responder Data for Rezpegaldesleukin
13 Oct 2023 //
PR NEWSWIRE
Nektar Announces Promising Data from Phase 1b Study of Rezpegaldesleukin
13 Sep 2023 //
PR NEWSWIRE
Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data
07 Aug 2023 //
PR NEWSWIRE
